Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells

Lisdexamfetamine dimesylate (LDX) is approved as a once-daily treatment for attention-deficit/hyperactivity disorder in children, adolescents, and adults in some countries. LDX is a prodrug comprising d-amphetamine covalently linked to l-lysine via a peptide bond. Following oral administration, LDX...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharman, Johannah, Pennick, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257105/
https://www.ncbi.nlm.nih.gov/pubmed/25489246
http://dx.doi.org/10.2147/NDT.S70382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257105/
https://www.ncbi.nlm.nih.gov/pubmed/25489246
http://dx.doi.org/10.2147/NDT.S70382

Ejemplares similares